Study links Actos with delayed dementia

Share this article:

Diabetes medication Actos could be repurposed for Alzheimer's disease. Reuters reports that a clinical trial indicates that the “cheap generic treatment” appears to be associated with delayed onset of the memory-eating disease.

Reuters notes that earlier studies indicated this may be a potential benefit, but this latest trial was a heftier effort, based on German healthcare data from 2004 through 2010 across a data set that included 146,000 patients ages 60 and older who did not initially show signs of dementia.

Researchers found that 13,841 patients eventually suffered dementia but the risk was reduced for every three months patients took Actos.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.